U.S. Army Identifies ChemImage for the 2011 Commercialization Pilot Program

ChemImage Corporation is one of 25 companies recently identified to participate in the U.S. Army Small Business Innovation Research (SBIR) 2011 Commercialization Pilot Program (CPP) for its real-time chemometrics and sensor fusion (RTCSF) technology.

Developed under a Phase II SBIR managed by the Army Research Office (ARO), ChemImage’s RTCSF technology will enable the real-time detection of chemical, biological and explosive threats. In 2011, the company will receive program support to accelerate its transition from research and development to commercial use.

“After rigorous analysis by U.S. Army SBIR, we’re pleased that the work being performed under the RTCSF project addresses high priority Army needs,” said Patrick Treado, PhD., Founder & Chief Technology Officer at ChemImage. “The support we’ll receive from the CPP will assist us in fielding this innovative ChemImage technology for use by Soldier Operators.”

Companies identified for CPP participation most strongly exemplify the program’s mission goals of addressing high priority Army needs, exhibiting the potential for accelerated transition and offering high commercialization potential. Program assistance includes: business and transition plan development, potential investment needs planning and justification, and facilitation of meetings with potential private and/or government customers. 

The U.S. Army established the SBIR CPP in 2007 in response to the 2006 National Defense Authorization Act, with the purpose of increasing SBIR technology transition and commercialization success.

About ChemImage Corporation

ChemImage Corporation is a Pittsburgh based company committed to making the world healthier and safer through dramatic advancements in chemical imaging technology. The company combines proprietary, state-of-the-art imaging sensors, algorithms and analytical software to solve the world's most challenging health and safety issues.

ChemImage seeks to provide an Awareness of Things™ (AoT™) to a global audience, using the company's innovation platforms to provide people with unprecedented levels of vision, information and situational knowledge about their surroundings in their everyday lives. To accomplish this goal, the firm develops technologies for chemical and biological applications across many global industries; including life sciences, bio-medical, security, threat detection, anatomic pathology, forensics and diagnostics. 

For more information, contact ChemImage.